Liposomal Curcumin Dosing Regimen for Cancer Toxicity Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing curcumin formulations face challenges in maximizing anti-proliferative activity while minimizing negative side effects, particularly due to poor bioavailability and systemic toxicity.
Innovation Solution
A dosing regimen involving intravenous administration of liposomal curcumin or curcuminoids at specific doses and intervals, combined with rest periods, to optimize therapeutic efficacy and minimize side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If oral administration of curcumin extract is used, then traditional medicine application is maintained, but bioavailability to tissues beyond gastrointestinal tract becomes negligible due to water insolubility and hepatic inactivation
Solution Approach 1:
The patent uses liposomes as intermediary carriers to deliver curcumin from the gastrointestinal tract to target tissues. The liposomal formulation protects curcumin from hepatic inactivation and enhances its solubility, allowing it to reach distant tissues effectively while maintaining the convenience of oral administration.
Solution Approach 2:
The patent changes the physical and chemical parameters of curcumin by formulating it within liposomal structures. This modification transforms curcumin from a water-insoluble compound with poor bioavailability to a lipid-associated formulation that can be effectively transported through the bloodstream to target tissues.
2Quantity of substance
If parenteral intravenous curcumin formulations are developed, then bioavailability to tissues is improved, but negative side effects and systemic toxicity increase
Solution Approach 1:
The patent employs targeted liposomal formulations that accumulate curcumin preferentially in tumor tissues through the enhanced permeability and retention (EPR) effect. This local concentration strategy improves anti-proliferative activity at the tumor site while minimizing exposure and toxicity to healthy systemic tissues.
Solution Approach 2:
The patent utilizes intermittent dosing regimens with treatment cycles separated by rest periods. This periodic administration allows tumor cells to be exposed to therapeutic levels of curcumin while providing intervals for normal tissue recovery, thereby reducing cumulative systemic toxicity.
3Productivity
If high dose curcumin is administered to maximize anti-proliferative activity, then therapeutic efficacy is improved, but negative side effects increase
Solution Approach 1:
The patent uses liposomes as protective intermediaries to deliver high doses of curcumin to tumors. The liposomal carrier shields healthy tissues from direct exposure to high concentrations of curcumin, enabling administration of therapeutically effective doses without proportionally increasing systemic side effects.
Solution Approach 2:
The patent employs rapid intravenous infusion of liposomal curcumin over short time periods (e.g., 15-30 minutes). This rapid delivery method allows high doses to be administered quickly, achieving therapeutic effect before significant systemic distribution and toxicity can occur, then the drug is cleared or redistributed to target tissues.
Data Source
AI summary
The present invention includes compositions and methods for treating a proliferative disorder comprising administering a therapeutically effective amount of an liposomal curcumin or curcuminoids to a human subject in need thereof in accordance with a dosing regimen comprising: at least one treatment cycle administering the therapeutically effective amount of the liposomal curcumin or curcuminoids once per week of at least 100 mg/m2 over 8 hours.